A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells

@inproceedings{Fahrenholtz2014ANC,
  title={A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells},
  author={Cale D. Fahrenholtz and Ann M. Greene and Pedro Jos{\'e} Villamizar Beltr{\'a}n and Kerry L Burnstein},
  booktitle={Oncotarget},
  year={2014}
}
Inhibition of the mitogenic insulin-like growth factor receptor 1 (IGF-1R) signaling axis is a compelling treatment strategy for prostate cancer. Combining the IGF-1R inhibitor ganitumab (formerly AMG 479) with standard of care androgen-deprivation therapy greatly delays prostate cancer recurrence in xenograft models; however, a significant proportion of these tumors ultimately acquire resistance to ganitumab. Here we describe the development of a stable and reproducible ganitumab-resistant… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 48 REFERENCES

A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2012
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

IGF1R signalling and its inhibition.

  • Endocrine-related cancer
  • 2006
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…